JP MORGAN/PUT/BOSTON SCIENTIFIC/52/0.1/21.06.24 | Market Closed - Börse Stuttgart 05:51:10 2024-06-10 am EDT | ||
| 0.001 EUR | -92.31% |
|
| Current month | -90.00% | ||
| 1 month | -88.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 0.001 | -92.31% |
| 24-06-07 | 0.013 | -13.33% |
| 24-06-06 | 0.015 | -16.67% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 05:51 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JL5PN7 |
| ISIN | DE000JL5PN79 |
| Date issued | 2023-06-23 |
| Strike | 52 $ |
| Maturity | 2024-06-21 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.7 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.05 € |
| Spread % | 98.04% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.76
USD
Average target price
82.26
USD
Spread / Average Target
+7.16%
- Stock Market
- Warrants
- Warrant
